Targeting T cells with specialized drugs to treat autoimmune diseases and cancers
Strategy for specific delivery of antisense oligonucleotides to T cells
This study is testing a new way to help deliver special treatments directly to T cells, which are important for fighting diseases like autoimmune disorders and some cancers, and patients may have a chance to join trials to see how well this method works.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Autoimmunity Biologic Solutions, INC. NIH-funded |
| Lab location | 1 site (Galveston, UNITED STATES) |
| Project ID | NIH-10547347 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to deliver antisense oligonucleotides (ASOs) specifically to T cells, which are crucial for immune response. The approach involves using specially designed monoclonal antibodies that can bind to T cell surface receptors, enhancing the delivery of ASOs to these immune cells. By improving the targeting of ASOs, the research aims to address conditions like autoimmune diseases and certain cancers that could benefit from better immunomodulation. Patients may have the opportunity to participate in trials that explore this innovative delivery system.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases or cancers that may benefit from targeted immunotherapy.
Not a fit: Patients with conditions unrelated to immune modulation or those who do not have T cell involvement in their disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for autoimmune diseases and cancers by improving how drugs are delivered to immune cells.
How similar studies have performed: While the approach of using monoclonal antibodies for targeted delivery is established, the specific application to T cells with ASOs is relatively novel and has not been extensively tested.
Where this research is happening
Galveston, UNITED STATES
- Autoimmunity Biologic Solutions, INC. — Galveston, United States (Active)
Researchers
- Principal investigator: Galarza-Munoz, Gaddiel — Autoimmunity Biologic Solutions, INC.
- Study coordinator: Galarza-Munoz, Gaddiel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.